A multi-institutional retrospective study comparing TKIs with or without RT for BM demonstrated that for the 53 ALK+ NSCLC patients included, there was no difference in time to intracranial progression or time to treatment failure, questioning the added benefit of RT (49). This evidence concerns the gene ALK and non-small cell lung carcinoma.